Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ascend Wellness HoldingsAAWH +4.84%45 3-Year EBITDA Growth Rate is 22.60% as of Mar. 2026, which is 36% below its 10-year median of 35.40. GuruFocus rates AAWH with a GF Scoreâ„¢ of 45/100 and a GF Valueâ„¢ of $0.73 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 809 Drug Manufacturers companies, Ascend Wellness Holdings ranks better than 72.56% on this metric.
During the past 12 months, Ascend Wellness Holdings's average EBITDA Per Share Growth Rate was -12.20% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 22.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Ascend Wellness Holdings was 48.20% per year. The lowest was 22.60% per year. And the median was 35.40% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Ascend Wellness Holdings 3-Year EBITDA Growth Rate Related Terms
AAWH vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ascend Wellness Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascend Wellness Holdings 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ascend Wellness Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Ascend Wellness Holdings's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 22.60% mean?
Ascend Wellness Holdings (AAWH) has a 3-Year EBITDA Growth Rate of 22.60% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Ascend Wellness Holdings and its competitors. This is 36% below median its historical median of 35.40. Over the past decade, Ascend Wellness Holdings' 3-Year EBITDA Growth Rate has ranged from 22.60 to 48.20. According to the industry distribution chart, Ascend Wellness Holdings ranks #222 out of 809 companies in the Drug Manufacturers industry, placing it in the top 27.4%.
Is Ascend Wellness Holdings' 3-Year EBITDA Growth Rate too high?
Ascend Wellness Holdings' current 3-Year EBITDA Growth Rate of 22.60% is 36% below median its 10-year median of 35.40. Over the past 10 years, this metric has ranged from a low of 22.60 to a high of 48.20. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Ascend Wellness Holdings' value of 22.60% is 153.9% above this industry median. Based on the distribution chart, Ascend Wellness Holdings ranks #222 out of 809 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Ascend Wellness Holdings has a GF Scoreâ„¢ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ascend Wellness Holdings' 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Ascend Wellness Holdings ranks #222 out of 809 companies for 3-Year EBITDA Growth Rate. This puts Ascend Wellness Holdings in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. Ascend Wellness Holdings' value of 22.60% is 153.9% above this benchmark. Historically, Ascend Wellness Holdings' own 3-Year EBITDA Growth Rate has ranged from 22.60 to 48.20 over the past decade. While the company's 10-year median is 35.40 vs. the industry median of 8.90, Ascend Wellness Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascend Wellness Holdings's current 3-Year EBITDA Growth Rate of 22.60% is 153.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Ascend Wellness Holdings and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascend Wellness Holdings's current 3-Year EBITDA Growth Rate is 22.60%, which is 36% below median its own 10-year median of 35.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascend Wellness Holdings stock overvalued right now?
Based on GuruFocus' analysis, Ascend Wellness Holdings (AAWH) is currently considered Possible Value Trap. The stock's GF Value™ is $0.73, compared to a current price of $0.44 — trading 40.4% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 22.60%, which is 36% below median its 10-year median of 35.40 and 153.9% above the Drug Manufacturers industry median of 8.90. Ascend Wellness Holdings' overall GF Score™ is 45/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Ascend Wellness Holdings (AAWH), the current 3-Year EBITDA Growth Rate is 22.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ascend Wellness Holdings (AAWH) Overvalued in 2026?
Based on GuruFocus' analysis, Ascend Wellness Holdings stock appears to be undervalued.
The current stock price of $0.44 is trading 40.4% below its estimated GF Value™ of $0.73.
GuruFocus considers Ascend Wellness Holdings to be Possible Value Trap.
Key valuation signals for AAWH:
3-Year EBITDA Growth Rate: 22.60% (36% below median its 10-year median of 35.40)
GF Value™: $0.73 vs. price of $0.44 (40.4% below fair value)
Industry Position: 153.9% above the Drug Manufacturers median (#222 of 809)
No single metric tells the full story. See the AAWH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ascend Wellness Holdings Inc is a vertically integrated multi-state operator focused on adult-use or near-term adult-use cannabis states in limited licenses markets. The company's core business is the cultivation, manufacturing, and distribution of cannabis consumer packaged goods, which it sells through company-owned retail stores and third-party licensed cannabis retail stores. It generates maximum revenue from the retail product segment.
45GF Score
Get the complete analysis for AAWH
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AAWH has been successfully added to your 
